We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.8B
AUM Growth
+$346M
Cap. Flow
-$15.3M
Cap. Flow %
-0.55%
Top 10 Hldgs %
76.91%
Holding
52
New
1
Increased
6
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$31.8M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$30.5M
3
CBIO
Crescent Biopharma
CBIO
+$27.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$11.7M
5
VSTM icon
Verastem
VSTM
+$8.17M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$36.5M
2
VERV
Verve Therapeutics
VERV
+$31.6M
3
ITOS
iTeos Therapeutics
ITOS
+$18.4M
4
XOMA
Xoma
XOMA
+$9.41M
5
THRD
Third Harmonic Bio
THRD
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
51
DELISTED
Verve Therapeutics
VERV
– –
-6,904,050
Closed -$31.6M
VIGL
52
DELISTED
Vigil Neuroscience
VIGL
– –
-4,013,633
Closed -$7.14M
1 2
3

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2025 Portfolio in Review

As of Q2 2025, BVF Inc held 52 positions worth $2.8B, up 14% from $2.45B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

BVF Inc's Q2 2025 filing shows 1 new, 6 increased, 7 reduced and 8 closed positions. Its largest new stake was Immunocore: 1,024,288 shares worth $32.1M. The largest sale was Lakefront Biotherapeutics American Depositary Shares, an estimated $36.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q2 2025 buy was Immunocore: 1,024,288 shares worth $32.1M.
  • BVF Inc added most to Protagonist Therapeutics in Q2 2025, an estimated $30.5M increase.
  • BVF Inc's biggest Q2 2025 reduction was Xoma, cutting an estimated $9.41M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q2 2025, selling an estimated $36.5M.
  • BVF Inc's ten largest holdings make up 77% of its $2.8B portfolio in Q2 2025.
  • BVF Inc opened 1 new position and closed 8 in Q2 2025.
  • BVF Inc's portfolio value rose 14% quarter-over-quarter to $2.8B.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.